Pioneer Group has teamed up with global healthcare company Novo Nordisk to launch a ‘Golden Ticket’ programme designed to help accelerate innovations in cardiometabolic health. The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare endocrine disorders. Ayokunmi Ajetunmobi, Head […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!